Tarsons Products
Tarsons delivered record quarterly revenue but gross margins are under severe pressure from surging crude-linked raw material costs.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Tarsons Products earnings call we streamed: the live audio and our summary of what management said.
Tarsons delivered record quarterly revenue but gross margins are under severe pressure from surging crude-linked raw material costs.
Tarsons delivered record quarterly revenue but gross margins are under severe pressure from surging crude-linked raw material costs.
Revenue potential of ₹800 Cr expected across old and new facilities by FY28.
Tarsons delivered record Q1 revenue growth of 21% YoY, yet profitability is severely squeezed by a 25-50% spike in raw material costs and heavy depreciation from new capex.
Tarsons reported record quarterly revenue of ₹121cr (Q4 FY26). Management is focused on ramping up newly commissioned bioprocess and cell culture facilities to drive long-term operating leverage.
Tarsons reported record quarterly revenue but margins were squeezed by raw material spikes and new plant costs.
Tarsons reported FY26 consolidated revenue growth of 8% to ₹422.5 cr, while PAT declined 48% to ₹15.5 cr due to high depreciation and finance costs from new facility capitalizations.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.